Winona Belmonte, MD
Psychiatry · Phoenix, AZNPI 1336227842
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$774
- AbbVie$641
- Otsuka America Pharmaceutical, Inc.$566
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,50298%
- Education$1332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 40 | $1,166 |
| Alkermes, Inc. | 39 | $1,081 |
| Johnson & Johnson | 40 | $1,074 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $774 |
| AbbVie(2 entities) | 43 | $641 |
| Otsuka America Pharmaceutical, Inc. | 30 | $566 |
| Neurocrine Biosciences, Inc. | 22 | $404 |
| Vanda Pharmaceuticals Inc. | 20 | $398 |
| Sunovion Pharmaceuticals Inc. | 25 | $350 |
| Indivior Inc. | 11 | $343 |
| E.r. Squibb & Sons, L.L.C. | 6 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $166 |
| Lundbeck LLC | 6 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $87 |
| Tris Pharma Inc | 4 | $69 |
| Eisai Inc. | 3 | $42 |
| Boston Scientific | 1 | $31 |
| Almatica Pharma LLC | 1 | $31 |
| Biogen | 1 | $25 |
| Braeburn Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- SPRAVATO$462
- AUSTEDO$265
- Austedo XR$235
- CAPLYTA$228
- INVEGA SUSTENNA$145
- INVEGA TRINZA$145
- SUBLOCADE$130
- ARISTADA INITIO$125
- COBENFY$125
How this compares
$7,635 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 90 | $327,676 |
| Austedo XrDeutetrabenazine | 16 | $203,699 |
| Abilify MaintenaAripiprazole | 55 | $152,673 |
| PerserisRisperidone | 36 | $113,031 |
| AustedoDeutetrabenazine | 16 | $112,534 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $45,072 |
| VraylarCariprazine Hcl | 18 | $27,172 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $23,504 |
| TrintellixVortioxetine Hydrobromide | 69 | $21,828 |
| Fluphenazine Hcl | 116 | $21,429 |
| Clozapine | 193 | $17,181 |
| Haloperidol Decanoate | 134 | $6,223 |
| Fluphenazine Decanoate | 38 | $4,386 |
| Divalproex Sodium ErDivalproex Sodium | 60 | $4,062 |
| Quetiapine Fumarate | 166 | $3,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,074 | $327,67690 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Loxapine | $1,166 | $317,22747 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $566 | $152,67355 claims |
| Indivior Inc.Perseris | $343 | $113,03136 claims |
| Alkermes, Inc.Lybalvi | $1,081 | $45,07226 claims |
| AbbVieVraylar | $641 | $27,17218 claims |
| Axsome Therapeutics, Inc.Auvelity | $15 | $23,50418 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $166 | $21,82869 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Eric ReimanPhoenix$157K
- Padma AkingPhoenix$44K
- Ahmed ElmaadawiPhoenix$32K
- Amnon KahanePhoenix$18K
- Aaron ClayPhoenix$14K
- Joel ParkerPhoenix$11K
- Ivan EngelPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.